EGFR and neoplasm: In conclusion, erlotinib offers a potentially cost-effective treatment option for the subgroup of predominantly poor performance patients with NSCLC with EGFR wild-type tumours who develop first-cycle rash and who are considered unfit by clinicians to be treated with first-line chemotherapy.